New Ascent Industries (NASDAQ: ACNT) directors join as buyback plan begins
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Ascent Industries Co. expanded its Board of Directors from five to seven members and appointed specialty chemicals veterans Carmen J. Giannantonio and Jeremy F. Rohen as independent directors, effective April 1, 2026. Both will serve on key committees, adding finance, M&A, and distribution expertise.
The company also adopted a Rule 10b5-1 trading plan to repurchase up to 1,750,000 shares of its common stock between March 31, 2026 and May 11, 2026 under its existing stock repurchase program. Director John P. Schauerman will not stand for re-election but will serve through the 2026 Annual Meeting.
Positive
- None.
Negative
- None.
Insights
Board is strengthened with sector experts as a sizable, pre-planned buyback window opens.
Ascent Industries is adding two independent directors with deep specialty chemicals, M&A, and distribution backgrounds while increasing board size from five to seven. This aligns board composition more closely with its pure-play specialty chemicals strategy and keeps audit, compensation, and governance committees fully staffed as a long-serving director prepares to rotate off.
The company also adopted a Rule 10b5-1 plan authorizing repurchases of up to 1,750,000 shares from March 31, 2026 to May 11, 2026 under its existing stock repurchase program. Such plans automate buybacks during blackout periods, making execution more systematic rather than opportunistic. Actual impact will depend on how many shares are ultimately repurchased within the plan’s parameters.
8-K Event Classification
3 items: 5.02, 8.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Form type: Form 8-K
Board size: Increased from 5 to 7 directors
Director age: 68 years
+5 more
8 metrics
Form type
Form 8-K
Current report detailing board changes and trading plan
Board size
Increased from 5 to 7 directors
Approved March 31, 2026
Director age
68 years
Age of new director Carmen J. Giannantonio
Director age
51 years
Age of new director Jeremy F. Rohen
Buyback plan size
1,750,000 shares
Maximum shares under Rule 10b5-1 plan
Plan start date
March 31, 2026
Effective date of Rule 10b5-1 trading plan
Plan end date
May 11, 2026
End date of Rule 10b5-1 trading plan
Transactions led
Over $200 billion
Transformational transactions led by Giannantonio in prior roles
Key Terms
Rule 10b5-1, stock repurchase program, indemnification agreement, Emerging growth company, +2 more
6 terms
Rule 10b5-1 regulatory
"adopted a written trading plan under Rule 10b5-1 of the Securities Exchange Act"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
stock repurchase program financial
"to facilitate the repurchase of its common stock pursuant to its stock repurchase program"
A stock repurchase program is when a company buys back its own shares from the market. This can make each remaining share more valuable and shows that the company believes its stock is a good investment. It’s like a business treating its shares like a limited resource, hoping to boost confidence and share prices.
indemnification agreement regulatory
"enter into our standard form of indemnification agreement with Mr. Giannantonio and Mr. Rohen"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
Emerging growth company regulatory
"Emerging growth company Item 5.02. Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Audit Committee financial
"will continue to serve as a director and chair of the Company's Audit Committee"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
Nominating and Corporate Governance Committee regulatory
"upon the recommendation of the Nominating and Corporate Governance Committee of the Board"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March 31, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
| (Registrant's telephone number, including area code) | ||||||||||||||
| (Former name or former address if changed since last report) | ||||||||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Director Appointments
On March 31, 2026, the Board of Directors (the "Board"), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved a resolution increasing the size of the Board from five to seven directors. Concurrently, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, unanimously approved the appointments of Carmen J. Giannantonio (age 68) and Jeremy F. Rohen (age 51) as a directors of the Company, to serve from April 1, 2026, until the next Annual Meeting of Stockholders (the "Annual Meeting") or until his successor is duly elected and qualified or until his earlier death, resignation or removal.
Carmen J. Giannantonio
Mr. Giannantonio has been a Director since November 1, 2023, on the Board of Delrin USA LLC, a global manufacturer of high-performance polyacetal homopolymer engineering plastics for automotive, healthcare and industrial applications. He has been a Director since June 30, 2023, and Vice Chairman of the Board of Trustees of Delaware Hospice, Inc., a non-profit community-based service organization providing comprehensive CMS-approved hospice, palliative care and grief support services for patients and families facing serious illness where he serves as Chairman of the Governance and Nominating committee, and a member of the Finance, Executive Compensation and Value-Based Care committees of the Board. Mr. Giannantonio has been a member of the Finance committee since May 1, 2023, of Ronald McDonald House of Delaware, a non-profit organization providing housing, care and support for families of seriously ill children. Mr. Giannantonio has an extensive executive corporate career with over 40 years in Finance and Strategy leadership positions including 23 years in Corporate Development with Fortune 500 companies in multi-industrial, pharmaceutical and specialty chemical industries where he planned and executed transformational transactions valued over $200 Billion, developed diverse global functions, managed and reported P&L performance, implemented corporate governance, successfully dealt with public company shareholder activists, and led strategic actions that generated sustainable and profitable growth. Mr. Giannantonio was formerly Vice President, Mergers & Acquisitions, DuPont de Nemours, Inc. (2019 – 2023); Sr. Director, Corporate Mergers & Acquisitions and Financial Planning & Analysis, E.I. DuPont de Nemours and Company (2009 – 2019); CFO, DuPont Imaging Technologies, a $1 Billion business segment of E.I. DuPont de Nemours and Company (2007 – 2009); Sr. Finance Director & Treasurer, Bristol Meyers Pharma (formerly known as DuPont Pharmaceuticals), and Director of Finance and Tax, DuPont Merck Pharmaceuticals, a global joint venture owned 50% by Merck, Inc. and 50% by E.I. DuPont de Nemours and Company.
Mr. Giannantonio holds a Master of Business Administration from Drexel University, a Master of Science in Taxation from Widener University and a Bachelor of Science in Accounting from Villanova University. He was previously a member of EY’s Corporate Development Leadership Network (2009 – 2023) and the National Association of Financial Professionals (1996 – 2023).
The Board has determined that Mr. Giannantonio qualifies as independent in accordance with the listing requirements of the Nasdaq Global Market. There were no arrangements or understandings pursuant to which Mr. Giannantonio was elected as a director, and there are no related party transactions or arrangements between the Company and Mr. Giannantonio reportable under Item 404(a) of Regulation S-K. Mr. Giannantonio will also serve on the Audit and Nominating and Corporate Governance Committees of the Board.
Jeremy F. Rohen
Mr. Rohen is the Co-Chief Executive Officer & Chief Operating Officer for Tilley Distribution, Inc. (Tilley), a global specialty ingredients and chemicals distributor. Prior to Tilley, Mr. Rohen served as Senior Vice President, Strategy and Business Development of Axalta Coating Systems Ltd., a leading global coatings company (NYSE: AXTA). Previously, Mr. Rohen served as Vice President, Corporate Development and Investor Relations for W.R. Grace & Co., a global specialty chemical and engineered materials company, where he led corporate development, strategy, treasury, and investor relations at W.R. Grace & Co. Prior to this, he was Managing Director for Seale & Associates, a Washington, DC based investment bank, and began his career at PricewaterhouseCoopers
Mr. Rohen holds a Master of Science in Taxation and a Bachelor of Science in Finance from The George Washington University School of Business.
The Board has determined that Mr. Rohen qualifies as independent in accordance with the listing requirements of the Nasdaq Global Market. There were no arrangements or understandings pursuant to which Mr. Rohen was elected as a director, and there are no related party transactions or arrangements between the Company and Mr. Rohen reportable under Item 404(a) of
Regulation S-K. Mr. Rohen will also serve on the Compensation and Nominating and Corporate Governance Committees of the Board.
For their services as independent directors, Mr. Giannantonio and Mr. Rohen will receive the same fees and compensation as other independent (non-employee) directors of the Company, determined on a pro rata basis. A description of the compensation paid to independent directors of the Company is set forth under the section entitled “Compensation of Non-Employee Directors” in the Company’s 2025 proxy statement filed on April 30, 2025. We also intend to enter into our standard form of indemnification agreement with Mr. Giannantonio and Mr. Rohen, which will obligate us to indemnify them to the fullest extent permitted by Delaware law.
Board Transition
On March 31, 2026, John Schauerman informed the Board of his decision not to stand for re-election as a member of the Board at the Company’s 2026 Annual Meeting. Mr. Schauerman will continue to serve as a director and chair of the Company's Audit Committee and member of the Board’s Compensation Committee and the Nominating and Corporate Governance Committee until the completion of his term. Mr. Schauerman’s decision not to stand for re-election as a member of the Board is not the result of any disagreement with the Company.
The Company issued a press release on April 1, 2026, announcing the appointment of Mr. Giannantonio and Mr. Rohen as well as the board transition for Mr. Schauerman. A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated by reference herein.
Item 8.01. Other Events
On March 31, 2026, Ascent Industries Co. (the “Company”) adopted a written trading plan under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (“Exchange Act”). The trading plan will include purchases up to the total amount of 1,750,000 shares executed daily based on specified price targets. This written trading plan will take effect on March 31, 2026 and will cease on May 11, 2026.
Adopting a trading plan that satisfies the conditions of Rule 10b5-1 allows a company to repurchase its shares at times when it might otherwise be prevented from doing so due to self-imposed trading blackout periods or pursuant to insider trading laws. A broker selected by the Company will have the authority under the terms and limitations specified in the plan to repurchase shares on the Company’s behalf in accordance with the terms of the plan. After the expiration of the current trading plan, the Company may from time to time enter into subsequent trading plans under Rule 10b5-1 to facilitate the repurchase of its common stock pursuant to its stock repurchase program.
Information regarding stock repurchases will be available in the Company’s periodic reports on Form 10-Q and 10-K filed with the Securities and Exchange Commission as required by the applicable rules of the Exchange Act.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
| Exhibit Number | Description of Exhibit | ||||
99.1 | Press Release dated April 1, 2026 | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on behalf by the undersigned hereunto duly authorized.
| Ascent Industries Co. | |||||
| Dated: April 1, 2026 | By: /s/ Ryan Kavalauskas | ||||
| Ryan Kavalauskas | |||||
| Chief Financial Officer | |||||
Exhibit 99.1
Ascent Industries Appoints Two Proven Specialty Chemicals Leaders to Board of Directors
Schaumburg, Illinois, April 1, 2026 -- Ascent Industries Co. (“Ascent” or the “Company”), a specialty chemicals platform delivering differentiated, performance-driven chemical solutions, today announced the appointment of Carmen J. Giannantonio and Jeremy F. Rohen to its Board of Directors, effective April 1, 2026.
These appointments reflect Ascent’s continued transformation into a pure-play specialty chemicals company and its commitment to aligning Board composition with the Company’s strategy.
Carmen J. Giannantonio
Mr. Giannantonio brings more than 40 years of experience in finance, corporate development, and strategy across leading specialty chemicals and industrial companies. He previously served as Vice President of Mergers & Acquisitions at DuPont de Nemours, Inc., where he led transformational transactions exceeding $200 billion in value.
Throughout his career, Mr. Giannantonio has played a central role in portfolio transformation, including major separations, acquisitions, and strategic repositioning initiatives that enhanced growth, reduced cyclicality, and improved returns on invested capital. He currently serves on the Board of Directors of Delrin USA LLC and brings deep expertise in corporate governance, capital allocation, and shareholder engagement.
Mr. Giannantonio holds a Master of Business Administration from Drexel University, a Master of Science in Taxation from Widener University and a Bachelor of Science in Accounting from Villanova University.
Jeremy Rohen
Mr. Rohen is Co-Chief Executive Officer and Chief Operating Officer of Tilley Distribution, Inc., a global distributor of specialty ingredients and chemicals. He brings extensive experience in high-service distribution models, strategic growth, and M&A execution across the specialty chemicals value chain.
Prior to Tilley, Mr. Rohen served as Senior Vice President, Strategy and Business Development at Axalta Coating Systems Ltd., and previously as Vice President of Corporate Development and Investor Relations at W. R. Grace & Co., where he led corporate development, strategy, treasury, and investor relations. Earlier in his career, he was a Managing Director at Seale & Associates and began his career at PricewaterhouseCoopers.
Mr. Rohen holds a Master of Science in Taxation and a Bachelor of Science in Finance from The George Washington University School of Business.
Leadership Commentary
Ben Rosenzweig, Chairman of the Board, and J. Bryan Kitchen, President and Chief Executive Officer, commented:
“Carmen and Jeremy bring highly relevant, real-world experience in specialty chemicals, distribution, and portfolio transformation, capabilities that will further strengthen our Board as we support the Company’s next phase of growth,” said Rosenzweig.
1
Exhibit 99.1
“Over the past two years, we have restructured Ascent into a pure-play specialty chemicals company and significantly strengthened the foundation of the business,” added Kitchen. “We are now focused on scaling that foundation, driving consistent execution, disciplined growth, and high-value outcomes for our customers and shareholders. Carmen and Jeremy bring a powerful combination of operating discipline, portfolio strategy, capital allocation rigor, and customer-centric commercial leadership. Importantly, they have deep experience across high-service manufacturing and distribution environments, where reliability, responsiveness, and technical partnership matter most. They have also consistently created value through thoughtful portfolio shaping and disciplined capital deployment, including M&A. Their perspectives will be instrumental as we continue to build a high-performance specialty chemicals platform.”
Board Transition
The Company also announced that John P. Schauerman, current Board member and Audit Committee Chair, will not stand for reelection to the Board.
Mr. Schauerman has served on Ascent’s Board since June 2020 and has played a pivotal role alongside management in driving transformational change across the Company’s compliance framework. His leadership and oversight have been instrumental in strengthening governance, enhancing internal controls, and positioning Ascent for its next phase of growth, with Ben Rosenzweig noting, “On behalf of the Board and management, we thank John for his meaningful contributions to Ascent over the past several years and wish him all the best in his future endeavors.”
About Ascent Industries Co.
Ascent Industries Co. (Nasdaq: ACNT) is a specialty chemicals platform delivering differentiated, performance-driven chemical solutions. For more information about Ascent, please visit its website at www.ascentco.com.
Investor Relations
1-630-844-9181
investorrelations@ascentco.com
2
FAQ
What board changes did Ascent Industries (ACNT) announce in this 8-K?
Ascent Industries expanded its Board from five to seven members and appointed Carmen J. Giannantonio and Jeremy F. Rohen as independent directors effective April 1, 2026. Both will serve on key committees, adding specialty chemicals, finance, M&A, and distribution expertise to support the company’s strategy.
Who are the new Ascent Industries (ACNT) directors and what experience do they bring?
The new directors are Carmen J. Giannantonio and Jeremy F. Rohen. Giannantonio brings over 40 years in finance, corporate development, and strategy at major chemical and industrial companies. Rohen adds operating and M&A experience from specialty chemicals distribution and prior senior strategy roles at Axalta and W.R. Grace.
Why did Ascent Industries (ACNT) adopt a Rule 10b5-1 trading plan for repurchases?
The Rule 10b5-1 plan allows Ascent to repurchase shares even during self-imposed blackout periods or when insider trading rules might otherwise restrict activity. By pre-establishing price targets and parameters, a broker can systematically execute buybacks on the company’s behalf under the stock repurchase program.
What did Ascent Industries disclose about director John P. Schauerman?
Ascent reported that director John P. Schauerman will not stand for re-election at the 2026 Annual Meeting. He will continue serving as a board member, Audit Committee chair, and member of other committees until his term ends. The company stated his decision does not reflect any disagreement.
How do the new directors’ roles align with Ascent Industries’ strategy?
The company highlighted that Giannantonio and Rohen support its transformation into a pure-play specialty chemicals business. Their backgrounds in portfolio transformation, capital allocation, distribution, and M&A are intended to help scale the platform, drive disciplined growth, and enhance returns for customers and shareholders.
Filing Exhibits & Attachments
4 documents
Ascent Industries Co.
NASDAQ:ACNT
ACNT Rankings
ACNT Latest News
ACNT Latest SEC Filings
Mar 31, 2026
[POS AM] ASCENT INDUSTRIES CO. SEC Filing